NCE-1 Intelligence & Market Opportunity

Vanflyta

Quizartinib

Anticancer

Tablet

Vanflyta is an oral medicine used with chemotherapy for adults newly diagnosed with FLT3‑ITD positive acute myeloid leukemia. It continues working as a maintenance therapy to help keep the cancer in check.

Approval Date

20-Jul-23

NCE-1 Date

20-Jul-27

NCE Date

20-Jul-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

24.90%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

100

2028

113

2029

129

2030

147

2031

159

2032

171

Molecule profile

Details & specifications

Molecule

Quizartinib

Innovator

DAIICHI SANKYO INC

Dosage Form

Tablet

Strength

17.7 mg and 26.5 mg base

Therapeutic Category

Anticancer

Usage

To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets